Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) and is spread through contact with the blood of an infected person.

**TREATMENT**

HCV infection is treated with medications intended to clear the virus from the body. These antiviral medications are highly effective and cure on average 95% of patients after 8-12 weeks of treatment.¹ ²

**GOAL OF THERAPY:**

The goal is to prevent the progression of the disease and to achieve sustained virologic response (SVR), a marker of the cure for Hepatitis C, meaning that the virus is no longer detectable in the blood 12 weeks after the patient completed treatment.³

**WHY SVR MATTERS**

Completing the full HCV treatment course is critical to cure the infection, eliminate the potential for transmission, improve quality of life, and avoid serious liver damage or even death. If SVR response is not achieved, getting the patient on the optimal therapy is key to preventing complications.²

**SHIELDS NETWORK OUTCOMES**

The goal is to prevent the progression of the disease and to achieve sustained virologic response (SVR), a marker of the cure for Hepatitis C, meaning that the virus is no longer detectable in the blood 12 weeks after the patient completed treatment.³

**SVR RATE**

<table>
<thead>
<tr>
<th>Shield Health Solutions</th>
<th>Benchmark SVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>98%</td>
<td>87%</td>
</tr>
</tbody>
</table>

**3 Common Barriers to the Treatment & Management of Hepatitis C**

1. HCV is often asymptomatic, causing underdiagnosis and undertreatment, along with a lack of awareness about new treatments

2. Challenges adhering to treatment, follow-up appointments, and lab testing requirements

3. High medication costs and limited healthcare access
**SHIELDS NETWORK OUTCOMES**

**Hepatitis C**

Our proven Shields care model breaks down barriers to care to optimize patient outcomes.

To help patients achieve SVR, Shields Health Solutions’ dedicated clinical team of pharmacists, liaisons and patient support advocates engage patients and their families to help educate, coordinate care and ensure patients receive specialty medication without significant delays.

---

**ENGAGE**

Our team engages with patients at the clinic and through telehealth appointments to educate them on the importance of therapy adherence and completing routine lab work.

**INTERVENE**

We provide side effect mitigation tactics, monitor for drug interactions, and analyze lab results to optimize medication therapy.

**COORDINATE**

Our team investigates patient insurance benefits, completes prior authorizations and identifies financial assistance opportunities so patients and providers can focus on their health, not paperwork.

**ENHANCE**

Through pharmacist, liaison and other interventions, our team can enhance patient care, provide emotional support, and help educate and coordinate care.

**RENEW**

Our experts provide ongoing education, stressing the importance of risk-reducing behaviors to help achieve SVR upon completion of therapy.

---

**SHIELDS CARE CONTINUUM**

**Engage**

FAs/PAs Completed (YTD)
Clinical staff utilizes their time to focus on patient care.

**Renew**

Patient Reported Treatment Efficacy
The percentage of patients with HCV infection who report feeling well with their specialty medications.

**Intervene**

Average COPay
Patients can access and afford treatment.

**Coordinate**

Average Time to Therapy
Patients start medication on time.

**Cost Avoidance**
Maximize cost avoidance.

**Financial Assistance**
Secured in 2022.

**Med Adherence**
(Proportion of Days Covered)
Patients receive, and take, medications on time.

---

* Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.

* All metrics are reflective of data collected in 2022.

---


* $ represents 85th percentile in 2022.